iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market

Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE)

-- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists

requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities

purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the

placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay

$500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate

In connection with the offering, the Company will

issue 1,559,828 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of $1.122 per share,

priced at-the-market under Nasdaq rules.

The offering is expected to close on or about

August 1, 2025, subject to the satisfaction of customary closing conditions.

WestPark Capital, Inc. is acting as the exclusive placement agent

in connection with the offering.

Additional details regarding the offering will

be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the "SEC").

The securities described above have not been registered

under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or

an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration

rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale

of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants.

This press release shall not constitute an offer

to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of any such state or jurisdiction.

iSpecimen (Nasdaq: ISPC) offers an online marketplace

for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to

patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for

specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations.

For more information, please visit www.ispecimen.com.

Safe Harbor Statement

Statements in this press release about future

expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking

statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate,"

"believe," "continue," "could," "estimate," "expect," "intend,"

"may," "plan," "potential," "predict," "project," "should," "target,"

"will," "would" and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such

forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should

consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market

conditions and the Company's ability to satisfy the closing conditions related to the Offering. These and other factors may cause

our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual

results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including

factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December

31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release

speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to

update any forward-looking statement, whether as a result of new information, future events or otherwise.